Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GERN - US3741631036 - Common Stock

1.31 USD
+0.01 (+0.77%)
Last: 1/16/2026, 8:22:40 PM
1.315 USD
+0 (+0.38%)
After Hours: 1/16/2026, 8:22:40 PM
Fundamental Rating

3

Overall GERN gets a fundamental rating of 3 out of 10. We evaluated GERN against 525 industry peers in the Biotechnology industry. GERN may be in some trouble as it scores bad on both profitability and health. GERN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • GERN had negative earnings in the past year.
  • In the past year GERN has reported a negative cash flow from operations.
  • GERN had negative earnings in each of the past 5 years.
  • In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -14.04%, GERN belongs to the top of the industry, outperforming 80.19% of the companies in the same industry.
  • GERN has a Return On Equity of -32.02%. This is in the better half of the industry: GERN outperforms 74.91% of its industry peers.
Industry RankSector Rank
ROA -14.04%
ROE -32.02%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 97.70%, GERN belongs to the best of the industry, outperforming 97.36% of the companies in the same industry.
  • GERN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

  • GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GERN has been increased compared to 1 year ago.
  • The number of shares outstanding for GERN has been increased compared to 5 years ago.
  • The debt/assets ratio for GERN is higher compared to a year ago.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -2.06, we must say that GERN is in the distress zone and has some risk of bankruptcy.
  • GERN has a Altman-Z score (-2.06) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.92 indicates that GERN is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.92, GERN is doing worse than 73.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC8.46%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • GERN has a Current Ratio of 5.96. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
  • GERN has a Current ratio of 5.96. This is in the better half of the industry: GERN outperforms 62.26% of its industry peers.
  • GERN has a Quick Ratio of 4.87. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.87, GERN is in line with its industry, outperforming 57.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.96
Quick Ratio 4.87
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

  • GERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
  • The Revenue has grown by 522.13% in the past year. This is a very strong growth!
  • Measured over the past years, GERN shows a very strong growth in Revenue. The Revenue has been growing by 178.45% on average per year.
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)522.13%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%67.05%

3.2 Future

  • Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.85% on average per year.
  • GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.91% yearly.
EPS Next Y57.19%
EPS Next 2Y35.28%
EPS Next 3Y30.34%
EPS Next 5Y26.85%
Revenue Next Year151.04%
Revenue Next 2Y85.5%
Revenue Next 3Y80.04%
Revenue Next 5Y58.91%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 0.3

4.3 Compensation for Growth

  • GERN's earnings are expected to grow with 30.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.28%
EPS Next 3Y30.34%

More info and screens

0

5. Dividend

5.1 Amount

  • GERN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GERON CORP

NASDAQ:GERN (1/16/2026, 8:22:40 PM)

After market: 1.315 +0 (+0.38%)

1.31

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners80.6%
Inst Owner Change0.71%
Ins Owners0.07%
Ins Owner Change1.33%
Market Cap836.25M
Revenue(TTM)183.40M
Net Income(TTM)-79.64M
Analysts78.46
Price Target3.4 (159.54%)
Short Float %11.98%
Short Ratio9.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.29%
Min EPS beat(2)10.87%
Max EPS beat(2)35.71%
EPS beat(4)4
Avg EPS beat(4)20.57%
Min EPS beat(4)10.87%
Max EPS beat(4)35.71%
EPS beat(8)8
Avg EPS beat(8)20.89%
EPS beat(12)11
Avg EPS beat(12)19.53%
EPS beat(16)13
Avg EPS beat(16)15.92%
Revenue beat(2)1
Avg Revenue beat(2)-4.92%
Min Revenue beat(2)-12.44%
Max Revenue beat(2)2.61%
Revenue beat(4)2
Avg Revenue beat(4)-6.81%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)2.61%
Revenue beat(8)5
Avg Revenue beat(8)159.07%
Revenue beat(12)6
Avg Revenue beat(12)107.74%
Revenue beat(16)9
Avg Revenue beat(16)189.91%
PT rev (1m)0%
PT rev (3m)-8.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.87%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-10.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.56
P/FCF N/A
P/OCF N/A
P/B 3.36
P/tB 3.36
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.29
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.04%
ROE -32.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.7%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.95%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.96
Quick Ratio 4.87
Altman-Z -2.06
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)153.53%
Cap/Depr(5y)161.21%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y57.19%
EPS Next 2Y35.28%
EPS Next 3Y30.34%
EPS Next 5Y26.85%
Revenue 1Y (TTM)522.13%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%67.05%
Revenue Next Year151.04%
Revenue Next 2Y85.5%
Revenue Next 3Y80.04%
Revenue Next 5Y58.91%
EBIT growth 1Y69.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.04%
EBIT Next 3Y19.08%
EBIT Next 5YN/A
FCF growth 1Y18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.91%
OCF growth 3YN/A
OCF growth 5YN/A

GERON CORP / GERN FAQ

Can you provide the ChartMill fundamental rating for GERON CORP?

ChartMill assigns a fundamental rating of 3 / 10 to GERN.


Can you provide the valuation status for GERON CORP?

ChartMill assigns a valuation rating of 1 / 10 to GERON CORP (GERN). This can be considered as Overvalued.


How profitable is GERON CORP (GERN) stock?

GERON CORP (GERN) has a profitability rating of 2 / 10.